Scailyte completes first close of series a round
Summary
The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology. The company is planning to establish further partnerships in immuno-oncology, and it is working on a custom solution to enable faster development of more robust cell therapies to enhance quality assessment of the manufacturing product, among other applications in this field. He is an Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. Formerly at Roche and a leader in the field of translational sciences, biomarkers and omics technologies, she is spearheading Scailyte’s discovery arm, the ScaiVision business unit. Anna is the CEO of Virometix, a University of Zurich spin-out company developing novel vaccines for the treatment and prevention of cancer and infectious diseases.